In this episode of the Applied Clinical Trials Podcast, C.K. Wang, MD, chief medical officer at COTA; and Sujay Jadhav, CEO ...
In today’s ACT Brief, we examine how the Verana Health-COTA merger is evolving real-world data use, the FDA’s new framework for individualized ultra-rare disease therapies, and what a decade of ...
“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these ...
In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease ...
At SCOPE Summit 2026, site leaders shared how AI is transforming feasibility, patient identification, and enrollment ...
Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening ...
Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.
Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial ...
In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and ...
In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...
In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is ...
In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results